MedTrace Logo

Study to Assess Efficacy and Safety of Bulevirtide in Combination With Pegylated Interferon Alfa-2a in Participants With Chronic Hepatitis Delta (CHD)

NCT03852433 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 175

Last updated 2024-10-08

Study results available
· View outcomes & findings →

Summary

The primary objective of this study is to evaluate the efficacy of bulevirtide in combination with pegylated interferon in participants with chronic hepatitis delta (CHD).

Conditions

Interventions

DRUG

Bulevirtide

Administered via subcutaneous injections

DRUG

Peginterferon Alfa-2a (PEG-IFN alfa)

Administered via subcutaneous injections

Sponsors & Collaborators

Principal Investigators

  • Gilead Medical Monitor · Gilead Sciences

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2019-05-31
Primary Completion
2022-04-05
Completion
2022-09-28
FDA Drug
Yes

Countries

  • France
  • Moldova
  • Romania
  • Russia

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03852433 on ClinicalTrials.gov